Care & Cure Organisation

Care & Cure Organisation Don't forget to follow

29/07/2025

Baby Movements in Pregnancy

đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ‚ āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻ•āϰāĻŦ⧇āύ āϕ⧀āĻ­āĻžāĻŦ⧇ āϜāĻžāύāĻž āωāϚāĻŋāϤāĨ¤ā§§) āĻŦā§āϝāĻĨāĻžāϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ:*đŸĢ€ āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦâ€ā§āϝāĻĨāĻž: āϏāĻžāϧāĻžāϰāĻŖāϤ āĻŦ⧁...
29/07/2025

đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ‚ āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻ•āϰāĻŦ⧇āύ āϕ⧀āĻ­āĻžāĻŦ⧇ āϜāĻžāύāĻž āωāϚāĻŋāϤāĨ¤

ā§§) āĻŦā§āϝāĻĨāĻžāϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ:
*đŸĢ€ āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦâ€ā§āϝāĻĨāĻž: āϏāĻžāϧāĻžāϰāĻŖāϤ āĻŦ⧁āϕ⧇āϰ āĻŽāĻžāĻāĻ–āĻžāύ⧇ āĻšā§ŸāĨ¤ āĻ…āύ⧇āĻ• āϏāĻŽā§Ÿ āĻŦā§āϝāĻĨāĻž āĻ—āϞāĻž, āĻšā§‹āρ⧟āĻžāϞ,āĻ•āĻžāρāϧ, āϘāĻžāĻĄāĻŧ āĻŦāĻž āĻšāĻžāϤ⧇ āĻ›āĻĄāĻŧāĻŋāϝāĻŧ⧇ āĻĒāĻĄāĻŧ⧇āĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āĻĒ⧇āĻŸā§‡āϰ āωāĻĒāϰ⧇āϰ āĻĻāĻŋāϕ⧇ (āύāĻžāĻ­āĻŋāϰ āĻ“āĻĒāϰ⧇, āĻŦ⧁āϕ⧇āϰ āύāĻŋāĻšā§‡) āĻšā§ŸāĨ¤

⧍) āĻŦā§āϝāĻĨāĻžāϰ āϏāĻŽāϝāĻŧāĻ•āĻžāϞ:
* đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž: āĻšāĻ āĻžā§Ž āĻļ⧁āϰ⧁, ā§Ģ-⧍ā§Ļ āĻŽāĻŋāύāĻŋāϟ āĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āϧ⧀āϰ⧇ āϧ⧀āϰ⧇ āĻļ⧁āϰ⧁, āĻĻā§€āĻ°ā§āϘ āϏāĻŽāϝāĻŧ āĻ¸ā§āĻĨāĻžā§Ÿā§€ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

ā§Š) āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āϏāĻžāĻĨ⧇ āϏāĻŽā§āĻĒāĻ°ā§āĻ•:
* đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž: āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āĻĒāϰ⧇ āĻŦāĻžā§œāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻ–āĻž: āĻ–āĻžāϞāĻŋ āĻĒ⧇āĻŸā§‡ āĻŦāĻž āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āĻĒāϰ⧇ āĻŦ⧇āĻĄāĻŧ⧇ āϝāĻžāϝāĻŧāĨ¤
āĻŽāϏāϞāĻž, āĻāĻžāϞ,āϚāĻ°ā§āĻŦāĻŋ āϜāĻžāϤ⧀āϝāĻŧ, āϤ⧈āϞāĻžāĻ•ā§āϤ āĻ–āĻžāĻŦāĻžāϰ⧇ āĻŦ⧇āĻļāĻŋ āĻšāϝāĻŧāĨ¤

ā§Ē) āĻŦā§āϝāĻĨāĻžāϰ āĻĒā§āϰāĻ•ā§ƒāϤāĻŋ:
* đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž: āϚāĻžāĻĒ āĻŦāĻž āĻ­āĻžāϰ⧀ āĻ•āĻŋāϛ⧁ āĻŦāϏ⧇ āφāϛ⧇ āĻāĻŽāύ āĻ…āύ⧁āĻ­ā§‚āϤāĻŋāĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹ā§œāĻž āĻŦāĻž āĻĨ⧇āĻŽā§‡ āĻĨ⧇āĻŽā§‡ āϤ⧀āĻŦā§āϰ āĻŦā§āϝāĻĨāĻžāĨ¤

ā§Ģ) āĻŦā§āϝāĻĨāĻžāϰ āϏāĻžāĻĨ⧇ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āωāĻĒāϏāĻ°ā§āĻ—:
* đŸĢ€āĻšāĻžāĻ°ā§āϟ āĻ…ā§āϝāĻžāϟāĻžāĻ• āĻšāϞ⧇: āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āϘāĻžāĻŽ, āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž,āĻŦāĻŽāĻŋ āĻŦāĻŽāĻŋ āĻ­āĻžāĻŦ āĻŦāĻž āĻŦāĻŽāĻŋ, āĻ…āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻšā§ƒāĻĻāĻ¸ā§āĻĒāĻ¨ā§āĻĻāύ, āĻ…āĻœā§āĻžāĻžāύ āĻšāĻ“āϝāĻŧāĻž āχāĻ¤â€ā§āϝāĻžāĻĻāĻŋāĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āĻ…āϰ⧁āϚāĻŋ, āĻŦāĻŽāĻŋ āĻ­āĻžāĻŦ āĻŦāĻž āĻŦāĻŽāĻŋ, āφāϞāĻ•āĻžāϤāϰāĻžāϰ āĻŽāϤ⧋ āĻ•āĻžāϞ⧋ āĻĒāĻžā§ŸāĻ–āĻžāύāĻž āĻŦāĻž āϰāĻ•ā§āϤ āĻŦāĻŽāĻŋ (āϜāϟāĻŋāϞāϤāĻž āĻšāϞ⧇)āĨ¤

ā§Ŧ) āĻ”āώāϧ⧇ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋāϝāĻŧāĻž:
* đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦâ€ā§āϝāĻĨāĻž: āĻŦāĻŋāĻļā§āϰāĻžāĻŽ āĻ“ āύāĻžāχāĻŸā§āϰ⧋āĻ—ā§āϞāĻŋāϏāĻžāϰāĻŋāύ⧇ āωāĻĒāĻļāĻŽ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻžāϏāĻŋāĻĄ āĻŦāĻž āĻ—ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻ“āώ⧁āϧ⧇ āĻ•āĻŽā§‡ āϝāĻžāϝāĻŧāĨ¤

ā§­) â™Ļī¸āĻœā§€āĻŦāύ⧇āϰ āĻā§āρāĻ•āĻŋ:
* đŸĢ€āĻšāĻžāĻ°ā§āϟ āĻ…ā§āϝāĻžāϟāĻžāĻ•: āϤāĻžā§ŽāĻ•ā§āώāĻŖāĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻž āύāĻŋāϞ⧇ āĻŽāĻžāϰāĻžāĻ¤ā§āĻŽāĻ• āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻŽā§ƒāĻ¤ā§āϝ⧁āĻšāĻžāϰ āĻ“ āϜāϟāĻŋāϞāϤāĻž āĻ…āύ⧇āĻ• āĻŦ⧇āĻļāĻŋāĨ¤
* āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž: āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒā§āϰāĻžāĻŖāϘāĻžāϤ⧀ āύāϝāĻŧ, āϤāĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āύāĻž āĻ•āϰāϞ⧇ āϜāϟāĻŋāϞāϤāĻž āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

** đŸĢ€āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž āĻšāϞ⧇ āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻŦâ€ā§āϝāĻĨāĻž āĻŽāύ⧇ āĻ•āϰ⧇ āĻ…āĻŦāĻšā§‡āϞāĻž āĻ•āϰāĻŦ⧇āύ āĻŦāĻž āĻļ⧁āϧ⧁ āĻ—â€ā§āϝāĻžāĻ¸ā§āĻŸā§āϰāĻŋāϕ⧇āϰ āĻ“āώ⧁āϧ āϖ⧇āϝāĻŧ⧇ āĻŦāϏ⧇ āĻĨāĻžāĻ•āĻŦ⧇āύ āύāĻžāĨ¤
āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻŦā§āϝāĻĨāĻž āĻšāϞ⧇ āĻĻā§āϰ⧁āϤ āĻšāĻžāϏāĻĒāĻžāϤāĻžāϞ⧇ āϝ⧇āϤ⧇ āĻšāĻŦ⧇āĨ¤

āϜāĻžāĻ¤ā§€ā§Ÿ āĻšā§ƒāĻĻāϰ⧋āĻ— āχāĻ¨ā§āϏāϟāĻŋāϟāĻŋāωāĻŸā§‡ āϚāϞāϛ⧇ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻĒāĻŋāϏāĻŋāφāχāĨ¤āϜāĻžāĻ¤ā§€ā§Ÿ āĻšā§ƒāĻĻāϰ⧋āĻ— āχāĻ¨ā§āϏāϟāĻŋāϟāĻŋāωāĻŸā§‡ āϚāϞāϛ⧇ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• āϰ⧋...
26/07/2025

āϜāĻžāĻ¤ā§€ā§Ÿ āĻšā§ƒāĻĻāϰ⧋āĻ— āχāĻ¨ā§āϏāϟāĻŋāϟāĻŋāωāĻŸā§‡ āϚāϞāϛ⧇ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻĒāĻŋāϏāĻŋāφāχāĨ¤
āϜāĻžāĻ¤ā§€ā§Ÿ āĻšā§ƒāĻĻāϰ⧋āĻ— āχāĻ¨ā§āϏāϟāĻŋāϟāĻŋāωāĻŸā§‡ āϚāϞāϛ⧇ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻĒāĻŋāϏāĻŋāφāχāĨ¤ āϚāϞāĻŦ⧇ āϰāĻžāϤ ā§ŽāϟāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤāĨ¤

āĻĒā§āϰāĻžāχāĻŽāĻžāϰāĻŋ āĻĒāĻŋāϏāĻŋāφāχ āĻĒāĻĻā§āϧāϤāĻŋāϤ⧇ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāĻ• (STEMI) āϰ⧋āĻ—ā§€āϰ āĻŦ⧁āĻ• āĻŦā§āϝāĻžāĻĨāĻž āĻļ⧁āϰ⧁ āĻšāĻŦāĻžāϰ ⧧⧍ āϘāĻ¨ā§āϟāĻžāϰ āĻŽāĻ§ā§āϝ⧇ āĻāύāϜāĻŋāĻ“āĻ—ā§āϰāĻžāĻŽ āĻ•āϰ⧇ āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āϰāĻ•ā§āϤāύāĻžāϞāĻŋāϰ āĻŦā§āϞāϕ⧇ āϏāϰāĻžāϏāϰāĻŋ āĻ¸ā§āĻŸā§‡āĻ¨ā§āϟ (āϰāĻŋāĻ‚) āĻĒāϰāĻŋā§Ÿā§‡ āĻŦā§āϞāĻ• āϖ⧁āϞ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāĨ¤ āĻŦāĻŋāĻļā§āĻŦāĻŦā§āϝāĻžāĻĒā§€ āĻšāĻžāĻ°ā§āϟ āĻāϟāĻžāϕ⧇āϰ āĻāϟāĻžāχ āϏāĻ°ā§āĻŦā§‹āĻ¤ā§āϤāĻŽ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāĨ¤

āĻāχ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻ–āϰāϚ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāύāĻžāĻŽā§‚āĻ˛ā§āϝ⧇ āϜāĻžāĻ¤ā§€ā§Ÿ āĻšā§ƒāĻĻāϰ⧋āĻ— āχāĻ¨ā§āϏāϟāĻŋāϟāĻŋāωāĻŸā§‡ āĻĻ⧇āĻ“ā§ŸāĻž āĻšāĻšā§āϛ⧇ āϏāĻ•āĻžāϞ ā§ŽāϟāĻž āĻĨ⧇āϕ⧇ āϰāĻžāϤ ā§ŽāϟāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤāĨ¤ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻ˜ā§‹āώāĻŖāĻž āύāĻž āĻĻ⧇āĻ“ā§ŸāĻž āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻāχ āϏ⧇āĻŦāĻž āĻĒā§āϰāϤāĻŋāĻĻāĻŋāύ āϚāϞāĻŦ⧇āĨ¤

āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āĻāĻ•āϟāĻŋ āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻā§€ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝāĻ—āϤ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āϝāĻž āϏāĻ āĻŋāĻ• āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāĻĒāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āĻāĻ•āϜāύ āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻāĻ•āϟāĻŋ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻĒā§...
24/07/2025

āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āĻāĻ•āϟāĻŋ āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻā§€ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝāĻ—āϤ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āϝāĻž āϏāĻ āĻŋāĻ• āĻŦā§āϝāĻŦāĻ¸ā§āĻĨāĻžāĻĒāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āĻāĻ•āϜāύ āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻāĻ•āϟāĻŋ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āϞ⧇āĻ–āĻž āĻ…āĻ¤ā§āϝāĻ¨ā§āϤ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

āĻāχ āĻĒā§‹āĻ¸ā§āĻŸā§‡ āφāĻŽāϰāĻž OPD (āφāωāϟāĻĄā§‹āϰ āĻĒ⧇āĻļ⧇āĻ¨ā§āϟ āĻĄāĻŋāĻĒāĻžāĻ°ā§āϟāĻŽā§‡āĻ¨ā§āϟ) āĻ āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āϞ⧇āĻ–āĻžāϰ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āĻĻāĻŋāĻ•āϗ⧁āϞ⧋ āφāϞ⧋āϚāύāĻž āĻ•āϰāĻŦāĨ¤

āχāύāϏ⧁āϞāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāĻ•āĻž
āχāύāϏ⧁āϞāĻŋāύ⧇āϰ āϧāϰāύ āĻāĻŦāĻ‚ āϤāĻžāĻĻ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻŦā§‹āĻāĻž āϜāϰ⧁āϰāĻŋ:
* āĻļāĻ°ā§āϟ-āĻ…ā§āϝāĻžāĻ•āϟāĻŋāĻ‚ āχāύāϏ⧁āϞāĻŋāύ: āĻāϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖāϤ 2HABF (⧍ āϘāĻŖā§āϟāĻž āφāĻĢāϟāĻžāϰ āĻŦā§āϰ⧇āĻ•āĻĢāĻžāĻ¸ā§āϟ), 2HAL (⧍ āϘāĻŖā§āϟāĻž āφāĻĢāϟāĻžāϰ āϞāĻžāĻžā§āϚ), āĻāĻŦāĻ‚ 2HAD (⧍ āϘāĻŖā§āϟāĻž āφāĻĢāϟāĻžāϰ āĻĄāĻŋāύāĻžāϰ) āĻāϰ āωāĻšā§āϚ āϰāĻ•ā§āϤ⧇ āĻļāĻ°ā§āĻ•āϰāĻž āĻ•āĻŽāĻžāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤ āĻāϟāĻŋ āĻĻāĻŋāύ⧇ āϤāĻŋāύāĻŦāĻžāϰ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāĨ¤

* āϞāĻ‚-āĻ…ā§āϝāĻžāĻ•āϟāĻŋāĻ‚ āχāύāϏ⧁āϞāĻŋāύ: āĻāχ āχāύāϏ⧁āϞāĻŋāύ FBS (āĻĢāĻžāĻ¸ā§āϟāĻŋāĻ‚ āĻŦā§āϞāĻžāĻĄ āϏ⧁āĻ—āĻžāϰ) āĻ•āĻŽāĻžāϤ⧇ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āĻāĻŦāĻ‚ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāĨ¤
* āχāĻ¨ā§āϟāĻžāϰāĻŽāĻŋāĻĄāĻŋāϝāĻŧ⧇āϟ-āĻ…ā§āϝāĻžāĻ•āϟāĻŋāĻ‚ āχāύāϏ⧁āϞāĻŋāύ: āĻāϟāĻŋ FBS āĻāĻŦāĻ‚ āĻĒā§‹āĻ¸ā§āϟ-āĻŽāĻŋāϞ āĻŦā§āϞāĻžāĻĄ āϏ⧁āĻ—āĻžāϰ āωāĻ­āϝāĻŧāχ āĻ•āĻŽāĻžāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇ āĻāĻŦāĻ‚ āĻĻāĻŋāύ⧇ āĻĻ⧁āχāĻŦāĻžāϰ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāĨ¤

āĻ“āϰāĻžāϞ āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋ-āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāĻ• āĻĄā§āϰāĻžāĻ—āϏ (OADs)
āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ āϧāϰāύ⧇āϰ āĻ“āϰāĻžāϞ āĻĄā§āϰāĻžāĻ—āϏ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύāĻ­āĻžāĻŦ⧇ āĻ•āĻžāϜ āĻ•āϰ⧇:
* FBS āĻ•āĻŽāĻžāϝāĻŧ āĻāĻŽāύ āĻ“āϰāĻžāϞ āĻĄā§āϰāĻžāĻ—āϏ:
* SFU (Sulfonylureas)
* Biguanides (āϝ⧇āĻŽāύ Metformin)
* TZD (Thiazolidinediones)
* SGLT2i (Sodium-Glucose Co-transporter 2 inhibitors): āĻāχ āĻĄā§āϰāĻžāĻ—āϗ⧁āϞāĻŋ FBS āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āφāĻĢāϟāĻžāϰ-āĻŽāĻŋāϞ āϏ⧁āĻ—āĻžāϰāĻ“ āĻ•āĻŽāĻžāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

* āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ 2HABF, 2HAL, 2HAD āĻ•āĻŽāĻžāϝāĻŧ āĻāĻŽāύ āĻĄā§āϰāĻžāĻ—āϏ:
* Glinides
* Gliptins (DPP-4 inhibitors)
* \alphaGSi (Alpha-Glucosidase inhibitors)
* GLP1a (GLP-1 receptor agonists)

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĢāĻŋāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻāĻ•ā§āϏāĻžāĻŽāĻŋāύ⧇āĻļāύ
āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻāχ ā§ŦāϟāĻŋ āĻĢāĻŋāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻāĻ•ā§āϏāĻžāĻŽāĻŋāύ⧇āĻļāύ āĻ…āĻ¤ā§āϝāĻ¨ā§āϤ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ:
* Cataract (āĻ›āĻžāύāĻŋ): āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ⧇āϰ āĻāĻ•āϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖ āϜāϟāĻŋāϞāϤāĻžāĨ¤
* Frozen Shoulder (āĻĢā§āϰ⧋āĻœā§‡āύ āĻļā§‹āĻ˛ā§āĻĄāĻžāϰ): āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻāϟāĻŋ āĻŦ⧇āĻļāĻŋ āĻĻ⧇āĻ–āĻž āϝāĻžāϝāĻŧāĨ¤
* Carpal Tunnel Syndrome (āĻ•āĻžāĻ°ā§āĻĒāĻžāϞ āϟāĻžāύ⧇āϞ āϏāĻŋāύāĻĄā§āϰ⧋āĻŽ): āĻ¸ā§āύāĻžāϝāĻŧāĻŦāĻŋāĻ• āϜāϟāĻŋāϞāϤāĻžāĨ¤
* Dorsalis Pedis Pulse Volume (āĻĄāϰāϏāĻžāϞāĻŋāϏ āĻĒ⧇āĻĄāĻŋāϏ āĻĒāĻžāϞāϏ āĻ­āϞāĻŋāωāĻŽ): āĻĒāĻžāϝāĻŧ⧇āϰ āϰāĻ•ā§āϤ ​​​​āϏāĻžā§āϚāĻžāϞāύ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ āϜāĻ¨ā§āϝāĨ¤
* Sensory Deficit (āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞāϤāĻžāϰ āĻ…āĻ­āĻžāĻŦ): āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāĻ• āύāĻŋāωāϰ⧋āĻĒā§āϝāĻžāĻĨāĻŋāϰ āϞāĻ•ā§āώāĻŖāĨ¤
* Romberg’s Sign (āϰ⧋āĻŽāĻŦ⧇āĻ°ā§āϗ⧇āϰ āϏāĻžāχāύ): āĻ­āĻžāϰāϏāĻžāĻŽā§āϝ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ āϜāĻ¨ā§āϝāĨ¤

āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āĻ•ā§āϝāĻžāĻŽā§āĻĒ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āχāύāϭ⧇āĻ¸ā§āϟāĻŋāϗ⧇āĻļāύ
āĻ•ā§āϝāĻžāĻŽā§āĻĒ āϏ⧇āϟāĻŋāĻ‚āϝāĻŧ⧇ āύāĻŋāĻŽā§āύāϞāĻŋāĻ–āĻŋāϤ ā§ŦāϟāĻŋ āχāύāϭ⧇āĻ¸ā§āϟāĻŋāϗ⧇āĻļāύ āϏāĻžāϧāĻžāϰāĻŖāϤ āωāĻĒāϞāĻŦā§āϧ āĻāĻŦāĻ‚ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ:
* Urine Sugar (āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇ āĻļāĻ°ā§āĻ•āϰāĻž)
* Urine Protein (āĻĒā§āϰāĻ¸ā§āϰāĻžāĻŦ⧇ āĻĒā§āϰ⧋āϟāĻŋāύ)
* RBS (āĻ°â€ā§āϝāĻžāĻ¨ā§āĻĄāĻŽ āĻŦā§āϞāĻžāĻĄ āϏ⧁āĻ—āĻžāϰ)
* ECG (āχāϞ⧇āĻ•ā§āĻŸā§āϰ⧋āĻ•āĻžāĻ°ā§āĻĄāĻŋāĻ“āĻ—ā§āϰāĻžāĻŽ)
* S. Creatinine (āϏ⧇āϰāĻžāĻŽ āĻ•ā§āϰāĻŋāϝāĻŧ⧇āϟāĻŋāύāĻŋāύ): āĻ•āĻŋāĻĄāύāĻŋāϰ āĻ•āĻžāĻ°ā§āϝāĻ•āĻžāϰāĻŋāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ āϜāĻ¨ā§āϝāĨ¤
* USG of Liver & Kidney (āϞāĻŋāĻ­āĻžāϰ āĻ“ āĻ•āĻŋāĻĄāύāĻŋāϰ āφāĻ˛ā§āĻŸā§āϰāĻžāϏāύ⧋āĻ—ā§āϰāĻžāĻŽ)

āχāύāϏ⧁āϞāĻŋāύ āĻŦāύāĻžāĻŽ āĻ“āϰāĻžāϞ āĻĄā§āϰāĻžāĻ— āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ
āύāĻŋāĻŽā§āύāϞāĻŋāĻ–āĻŋāϤ ā§ŦāϟāĻŋ āĻŦāĻŋāώāϝāĻŧ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āχāύāϏ⧁āϞāĻŋāύ āĻŦāĻž āĻ“āϰāĻžāϞ āĻĄā§āϰāĻžāĻ— āĻĨ⧇āϰāĻžāĻĒāĻŋ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāĻž āĻšāϝāĻŧ:
* FBS (āĻĢāĻžāĻ¸ā§āϟāĻŋāĻ‚ āĻŦā§āϞāĻžāĻĄ āϏ⧁āĻ—āĻžāϰ) āϞ⧇āϭ⧇āϞ
* 2HABF (⧍ āϘāĻŖā§āϟāĻž āφāĻĢāϟāĻžāϰ āĻŦā§āϰ⧇āĻ•āĻĢāĻžāĻ¸ā§āϟ) āϞ⧇āϭ⧇āϞ
* HbA1C (āĻ—ā§āϞāĻžāχāϕ⧇āĻŸā§‡āĻĄ āĻšāĻŋāĻŽā§‹āĻ—ā§āϞ⧋āĻŦāĻŋāύ) āϞ⧇āϭ⧇āϞ: āĻ—āϤ ⧍-ā§Š āĻŽāĻžāϏ⧇āϰ āĻ—āĻĄāĻŧ āϰāĻ•ā§āϤ⧇ āĻļāĻ°ā§āĻ•āϰāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰ⧇āĨ¤
* Comorbidity in Liver, Kidney & Heart (āϞāĻŋāĻ­āĻžāϰ, āĻ•āĻŋāĻĄāύāĻŋ āĻāĻŦāĻ‚ āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āϏāĻš-āĻ…āĻŦāĻ¸ā§āĻĨāĻž): āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻžāĨ¤
* Diabetic Complication (āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāĻ• āϜāϟāĻŋāϞāϤāĻž): āχāϤāĻŋāĻŽāĻ§ā§āϝ⧇ āϕ⧋āύ āϜāϟāĻŋāϞāϤāĻž āφāϛ⧇ āĻ•āĻŋāύāĻžāĨ¤
* Economic & Logistic support for insulin therapy (āχāύāϏ⧁āϞāĻŋāύ āĻĨ⧇āϰāĻžāĻĒāĻŋāϰ āϜāĻ¨ā§āϝ āĻ…āĻ°ā§āĻĨāύ⧈āϤāĻŋāĻ• āĻ“ āϞāϜāĻŋāĻ¸ā§āϟāĻŋāĻ• āϏāĻšāĻžāϝāĻŧāϤāĻž): āϰ⧋āĻ—ā§€āϰ āχāύāϏ⧁āϞāĻŋāύ āϕ⧇āύāĻžāϰ āϏāĻžāĻŽāĻ°ā§āĻĨā§āϝ āĻāĻŦāĻ‚ āϏāĻ āĻŋāĻ•āĻ­āĻžāĻŦ⧇ āϏāĻ‚āϰāĻ•ā§āώāϪ⧇āϰ āϏ⧁āĻŦāĻŋāϧāĻžāĨ¤

āĻāχ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāĻ•āĻžāϟāĻŋ āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϰ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āϞ⧇āĻ–āĻžāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•āĻĻ⧇āϰ āϏāĻšāĻžāϝāĻŧāϤāĻž āĻ•āϰāĻŦ⧇ āĻŦāϞ⧇ āφāĻļāĻž āĻ•āϰāĻŋāĨ¤

āϏāĻ āĻŋāĻ• āϏāĻŽāϝāĻŧ⧇ āϏāĻ āĻŋāĻ• āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻāĻ•āϜāύ āĻĄāĻžāϝāĻŧāĻžāĻŦ⧇āϟāĻŋāϏ āϰ⧋āĻ—ā§€āϕ⧇ āϏ⧁āĻ¸ā§āĻĨ āĻœā§€āĻŦāύāϝāĻžāĻĒāύ āĻ•āϰāϤ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

āφāĻĒāύāĻžāϰ āĻŽā§‚āĻ˛ā§āϝāĻŦāĻžāύ āĻŽāϤāĻžāĻŽāϤ āĻ•āĻŽā§‡āĻ¨ā§āĻŸā§‡ āϜāĻžāύāĻžāϤ⧇ āĻĒāĻžāϰ⧇āύ!

āĻ-āχ āϏāĻŋāϜāύ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ,āĻāϞāĻžāĻ°ā§āϜāĻŋ,āύāĻžāĻ• āĻĻāĻŋāϝāĻŧ⧇ āĻĒāĻžāύāĻŋ āĻāϰāĻžāϰ āϏāĻšāϜ āϏāĻŽāĻžāϧāĻžāύ!🤗ā§Ļ+ā§Ļ+ā§§āĻŦāĻžāĻšā§āϚāĻžāĻĻ⧇āϰ āϜāĻ¨ā§āϝ āϏāĻŋāϰāĻžāĻĒ āφāϛ⧇āĨ¤ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒā§‚āĻ°ā§āĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽ...
06/07/2025

āĻ-āχ āϏāĻŋāϜāύ⧇ āϚ⧁āϞāĻ•āĻžāύāĻŋ,āĻāϞāĻžāĻ°ā§āϜāĻŋ,āύāĻžāĻ• āĻĻāĻŋāϝāĻŧ⧇ āĻĒāĻžāύāĻŋ āĻāϰāĻžāϰ āϏāĻšāϜ āϏāĻŽāĻžāϧāĻžāύ!🤗

ā§Ļ+ā§Ļ+ā§§

āĻŦāĻžāĻšā§āϚāĻžāĻĻ⧇āϰ āϜāĻ¨ā§āϝ āϏāĻŋāϰāĻžāĻĒ āφāϛ⧇āĨ¤
āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒā§‚āĻ°ā§āĻŦ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āύāĻŋāύāĨ¤

Recent Outbreak of Monkeypox Virus in several countries: Overview of the DiseaseMonkeypox cases have been reported in se...
18/08/2024

Recent Outbreak of Monkeypox Virus in several countries: Overview of the Disease

Monkeypox cases have been reported in several countries in Africa such as Congo and Pakistan recently. The World Health Organization (WHO) announced on 14 August 2024 that it declared MPox a ‘public health emergency of international concern.

Monkeypox is a viral zoonosis (a virus transmitted to humans from animals) with symptoms very similar to those seen in the past in smallpox patients, although it is clinically less severe. Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family.

The natural reservoir of monkeypox remains unknown. However, African rodents and non-human primates (like monkeys) may harbor the virus and infect people.

Monkeypox virus is transmitted from one person to another by close contact with lesions, body fluids, respiratory droplets and contaminated materials such as bedding.

While close physical contact is a well-known risk factor for transmission, it is unclear at this time if monkeypox can be transmitted specifically through sexual transmission routes

Signs and symptoms

Monkeypox is usually a self-limited disease with symptoms lasting from 2 to 4 weeks. Severe cases can occur. Recently, the case fatality ratio has been around 3-6%.

The Incubation period (interval from infection to onset of symptoms) of monkeypox is usually from 7 to 14 days but can range from 5 to 21 days.

The Prodrome period (lasts between 0-5 days) is characterized by fever, intense headache, lymphadenopathy (swelling of the lymph nodes), back pain, myalgia (muscle aches) and intense asthenia (lack of energy).

Lymphadenopathy is a distinctive feature of monkeypox compared to other diseases that may initially appear similar (chickenpox, measles, smallpox).

The Eruptive period (skin eruption/rash) usually begins within 1-3 days of the appearance of fever. The rash tends to be more concentrated on the face and extremities rather than on the trunk. It affects the face (in 95% of cases), and palms of the hands and soles of the feet (in 75% of cases). Also affected are oral mucous membranes (in 70% of cases), genitalia (30%), and conjunctivae (20%), as well as the cornea.

The rash evolves sequentially from macules (lesions with a flat base) to papules (slightly raised firm lesions), vesicles (lesions filled with clear fluid), pustules (lesions filled with yellowish fluid), and crusts/scabs which dry up and fall off.

The number of lesions varies from a few to several thousand. In severe cases, lesions can coalesce until large sections of skin slough off.

Diagnosis

A definite diagnosis of monkeypox requires assessment by a health professional and specific testing in a specialist laboratory.

The clinical differential diagnosis that must be considered includes other rash illnesses, such as chickenpox, measles, bacterial skin infections, scabies, syphilis, and medication-associated allergies.

Lymphadenopathy during the prodromal stage of illness can be a clinical feature to distinguish monkeypox from chickenpox or smallpox.

Polymerase chain reaction (PCR) is the preferred laboratory test given its accuracy and sensitivity. For this, optimal diagnostic samples for monkeypox are from skin lesions – the roof or fluid from vesicles and pustules, and dry crusts. Where feasible, the biopsy is an option.

--------------------------------------------------------------------------------------------------
āĻŦ⧇āĻļ āĻ•āϝāĻŧ⧇āĻ•āϟāĻŋ āĻĻ⧇āĻļ⧇ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āĻ­āĻžāχāϰāĻžāϏ⧇āϰ āϏāĻžāĻŽā§āĻĒā§āϰāϤāĻŋāĻ• āĻĒā§āϰāĻžāĻĻ⧁āĻ°ā§āĻ­āĻžāĻŦ: āϰ⧋āϗ⧇āϰ āĻ“āĻ­āĻžāϰāĻ­āĻŋāω

āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āĻ™ā§āĻ—ā§‹ āĻāĻŦāĻ‚ āĻĒāĻžāĻ•āĻŋāĻ¸ā§āϤāĻžāύ⧇āϰ āĻŽāϤ⧋ āφāĻĢā§āϰāĻŋāĻ•āĻžāϰ āĻŦ⧇āĻļ āĻ•āϝāĻŧ⧇āĻ•āϟāĻŋ āĻĻ⧇āĻļ⧇ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āϘāϟāύāĻž āϘāĻŸā§‡āϛ⧇āĨ¤ āĻŦāĻŋāĻļā§āĻŦ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āϏāĻ‚āĻ¸ā§āĻĨāĻž (āĻĄāĻŦā§āϞāĻŋāωāĻāχāϚāĻ“) 14 āφāĻ—āĻ¸ā§āϟ 2024 āĻ āĻ˜ā§‹āώāĻŖāĻž āĻ•āϰ⧇āϛ⧇ āϝ⧇ āĻāϟāĻŋ āĻāĻŽāĻĒāĻŋāĻ•ā§āϏāϕ⧇ 'āφāĻ¨ā§āϤāĻ°ā§āϜāĻžāϤāĻŋāĻ• āωāĻĻā§āĻŦ⧇āϗ⧇āϰ āϜāύāĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āϜāϰ⧁āϰāĻŋ āĻ…āĻŦāĻ¸ā§āĻĨāĻž āĻ˜ā§‹āώāĻŖāĻž āĻ•āϰ⧇āϛ⧇āĨ¤

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āĻšāϞ āĻāĻ•āϟāĻŋ āĻ­āĻžāχāϰāĻžāϞ āϜ⧁āύ⧋āϏāĻŋāϏ (āĻĒā§āϰāĻžāĻŖā§€ āĻĨ⧇āϕ⧇ āĻŽāĻžāύ⧁āώ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŋāϤ āĻāĻ•āϟāĻŋ āĻ­āĻžāχāϰāĻžāϏ) āϝāĻžāϰ āϞāĻ•ā§āώāĻŖāϗ⧁āϞāĻŋ āĻ…āϤ⧀āϤ⧇ āϗ⧁āϟāĻŋāĻŦāϏāĻ¨ā§āϤ⧇āϰ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻĻ⧇āĻ–āĻž āϝāĻžāϝāĻŧ āĻāĻŽāύ āϞāĻ•ā§āώāĻŖāϗ⧁āϞāĻŋāϰ āĻŽāϤ⧋, āϝāĻĻāĻŋāĻ“ āĻāϟāĻŋ āϚāĻŋāĻ•āĻŋāĻ¤ā§āϏāĻžāĻ—āϤāĻ­āĻžāĻŦ⧇ āĻ•āĻŽ āϗ⧁āϰ⧁āϤāϰāĨ¤ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āĻ­āĻžāχāϰāĻžāϏ āĻšāϞ āĻāĻ•āϟāĻŋ āĻāύāϭ⧇āϞāĻĒāĻĄ āĻĄāĻŦāϞ-āĻ¸ā§āĻŸā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄā§‡āĻĄ āĻĄāĻŋāĻāύāĻ āĻ­āĻžāχāϰāĻžāϏ āϝāĻž āĻĒāĻ•ā§āϏāĻ­āĻŋāϰāĻŋāĻĄā§‡ āĻĒāϰāĻŋāĻŦāĻžāϰ⧇āϰ āĻ…āĻ°ā§āĻĨā§‹āĻĒāĻ•ā§āϏāĻ­āĻžāχāϰāĻžāϏ āĻ—āϪ⧇āϰ āĻ…āĻ¨ā§āϤāĻ°ā§āĻ—āϤāĨ¤

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āĻĒā§āϰāĻžāĻ•ā§ƒāϤāĻŋāĻ• āφāϧāĻžāϰ āĻ…āϜāĻžāύāĻž āϰāϝāĻŧ⧇ āϗ⧇āϛ⧇āĨ¤ āϝāĻžāχāĻšā§‹āĻ•, āφāĻĢā§āϰāĻŋāĻ•āĻžāύ āχāρāĻĻ⧁āϰ āĻāĻŦāĻ‚ āĻ…-āĻŽāĻžāύāĻŦ āĻĒā§āϰāĻžāχāĻŽā§‡āϟ (āĻŦāĻžāύāϰ⧇āϰ āĻŽāϤ⧋) āĻ­āĻžāχāϰāĻžāϏāϕ⧇ āφāĻļā§āϰāϝāĻŧ āĻ•āϰ⧇ āĻāĻŦāĻ‚ āĻŽāĻžāύ⧁āώāϕ⧇ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŋāϤ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āĻ­āĻžāχāϰāĻžāϏ āĻ•ā§āώāϤ, āĻļāϰ⧀āϰ⧇āϰ āϤāϰāϞ, āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āĻŸā§‡āϰ āĻĢā§‹āρāϟāĻž āĻāĻŦāĻ‚ āĻŦāĻŋāĻ›āĻžāύāĻžāϰ āĻŽāϤ⧋ āĻĻā§‚āώāĻŋāϤ āĻĒāĻĻāĻžāĻ°ā§āĻĨ⧇āϰ āϏāĻžāĻĨ⧇ āϘāύāĻŋāĻˇā§āĻ  āϝ⧋āĻ—āĻžāϝ⧋āϗ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻāĻ•āϜāύ āĻĨ⧇āϕ⧇ āĻ…āĻ¨ā§āϝ āĻŦā§āϝāĻ•ā§āϤāĻŋāϤ⧇ āĻĒā§āϰ⧇āϰāĻŖ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

āϝāĻĻāĻŋāĻ“ āϘāύāĻŋāĻˇā§āĻ  āĻļāĻžāϰ⧀āϰāĻŋāĻ• āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϜāĻ¨ā§āϝ āĻāĻ•āϟāĻŋ āϏ⧁āĻĒāϰāĻŋāϚāĻŋāϤ āĻā§āρāĻ•āĻŋāϰ āĻ•āĻžāϰāĻŖ, āϤāĻŦ⧇ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āϝ⧌āύ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āϰ⧁āĻŸā§‡āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āĻ•āĻŋāύāĻž āϤāĻž āĻāχ āϏāĻŽāϝāĻŧ⧇ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟāĨ¤

āϞāĻ•ā§āώāĻŖ āĻ“ āωāĻĒāϏāĻ°ā§āĻ—

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻ•āϟāĻŋ āĻ¸ā§āĻŦ-āϏ⧀āĻŽāĻŋāϤ āϰ⧋āĻ— āϝāĻžāϰ āϞāĻ•ā§āώāĻŖ 2 āĻĨ⧇āϕ⧇ 4 āϏāĻĒā§āϤāĻžāĻš āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āĻšāϝāĻŧāĨ¤ āϗ⧁āϰ⧁āϤāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϘāϟāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϏāĻŽā§āĻĒā§āϰāϤāĻŋ, āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻŽā§ƒāĻ¤ā§āϝ⧁āϰ āĻ…āύ⧁āĻĒāĻžāϤ āĻĒā§āϰāĻžāϝāĻŧ 3-6% āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āχāύāĻ•āĻŋāωāĻŦ⧇āĻļāύ āĻĒāĻŋāϰāĻŋāϝāĻŧāĻĄ (āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ āĻĨ⧇āϕ⧇ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϏ⧂āĻ¤ā§āϰāĻĒāĻžāϤ āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻŦā§āϝāĻŦāϧāĻžāύ) āϏāĻžāϧāĻžāϰāĻŖāϤ 7 āĻĨ⧇āϕ⧇ 14 āĻĻāĻŋāύ āĻšāϝāĻŧ āϤāĻŦ⧇ 5 āĻĨ⧇āϕ⧇ 21 āĻĻāĻŋāύ āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻĒā§āϰāĻĄā§āϰ⧋āĻŽ āϏāĻŽāϝāĻŧāĻ•āĻžāϞ (0-5 āĻĻāĻŋāύ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āĻšāϝāĻŧ) āĻœā§āĻŦāϰ, āϤ⧀āĻŦā§āϰ āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āϞāĻŋāĻŽā§āĻĢā§āϝāĻžāĻĄā§‡āύ⧋āĻĒā§āϝāĻžāĻĨāĻŋ (āϞāĻŋāĻŽā§āĻĢ āύ⧋āĻĄā§‡āϰ āĻĢā§‹āϞāĻž), āĻĒāĻŋāϠ⧇ āĻŦā§āϝāĻĨāĻž, āĻŽāĻžāϝāĻŧāĻžāϞāϜāĻŋāϝāĻŧāĻž (āĻĒ⧇āĻļā§€āϤ⧇ āĻŦā§āϝāĻĨāĻž) āĻāĻŦāĻ‚ āϤ⧀āĻŦā§āϰ āĻ…ā§āϝāĻžāĻĨ⧇āύāĻŋāϝāĻŧāĻž (āĻļāĻ•ā§āϤāĻŋāϰ āĻ…āĻ­āĻžāĻŦ) āĻĻā§āĻŦāĻžāϰāĻž āϚāĻŋāĻšā§āύāĻŋāϤ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

āϞāĻŋāĻŽā§āĻĢā§āϝāĻžāĻĄā§‡āύ⧋āĻĒā§āϝāĻžāĻĨāĻŋ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϰ⧋āϗ⧇āϰ āϤ⧁āϞāύāĻžāϝāĻŧ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āĻāĻ•āϟāĻŋ āĻ¸ā§āĻŦāϤāĻ¨ā§āĻ¤ā§āϰ āĻŦ⧈āĻļāĻŋāĻˇā§āĻŸā§āϝ āϝāĻž āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āĻāĻ•āχ āϰāĻ•āĻŽ āĻĻ⧇āĻ–āĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇ (āϚāĻŋāϕ⧇āύāĻĒāĻ•ā§āϏ, āĻšāĻžāĻŽ, āϗ⧁āϟāĻŋāĻŦāϏāĻ¨ā§āϤ)āĨ¤

āχāϰāĻžāĻĒāϟāĻŋāĻ­ āĻĒāĻŋāϰāĻŋāϝāĻŧāĻĄ (āĻ¤ā§āĻŦāϕ⧇āϰ āĻŦāĻŋāĻ¸ā§āĻĢā§‹āϰāĻŖ/āĻĢ⧁āϏāϕ⧁āĻĄāĻŧāĻŋ) āϏāĻžāϧāĻžāϰāĻŖāϤ āĻœā§āĻŦāϰ āĻšāĻ“āϝāĻŧāĻžāϰ 1-3 āĻĻāĻŋāύ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻļ⧁āϰ⧁ āĻšāϝāĻŧāĨ¤ āĻĢ⧁āϏāϕ⧁āĻĄāĻŧāĻŋ āĻ•āĻžāĻŖā§āĻĄā§‡āϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤ⧇ āĻŽā§āĻ– āĻāĻŦāĻ‚ āĻšāĻžāϤ⧇āϰ āĻĻāĻŋāϕ⧇ āĻŦ⧇āĻļāĻŋ āϘāύ⧀āĻ­ā§‚āϤ āĻšāϤ⧇ āĻĨāĻžāϕ⧇āĨ¤ āĻāϟāĻŋ āĻŽā§āĻ–āϕ⧇ āĻĒā§āϰāĻ­āĻžāĻŦāĻŋāϤ āĻ•āϰ⧇ (95% āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇), āĻāĻŦāĻ‚ āĻšāĻžāϤ⧇āϰ āϤāĻžāϞ⧁ āĻāĻŦāĻ‚ āĻĒāĻžāϝāĻŧ⧇āϰ āϤāϞāĻžāϝāĻŧ (75% āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇)āĨ¤ āĻāĻ›āĻžāĻĄāĻŧāĻžāĻ“ āĻŽā§āϖ⧇āϰ āĻļā§āϞ⧇āĻˇā§āĻŽāĻž āĻāĻŋāĻ˛ā§āϞāĻŋ (70% āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇), āϝ⧌āύāĻžāĻ™ā§āĻ— (30%), āĻāĻŦāĻ‚ āĻ•āύāϜāĻžāĻ‚āϟāĻŋāĻ­āĻž (20%) āĻāĻŦāĻ‚ āĻ•āĻ°ā§āύāĻŋāϝāĻŧāĻžāĻ“ āφāĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻšāϝāĻŧāĨ¤

āĻĢ⧁āϏāϕ⧁āĻĄāĻŧāĻŋ āĻ•ā§āϰāĻŽāĻžāĻ—āϤāĻ­āĻžāĻŦ⧇ āĻŽā§āϝāĻžāϕ⧁āϞāϏ (āĻāĻ•āϟāĻŋ āϏāĻŽāϤāϞ āĻŦ⧇āϏ āϏāĻš āĻ•ā§āώāϤ) āĻĨ⧇āϕ⧇ āĻĒā§āϝāĻžāĻĒāĻŋāωāϞāϏ (āϏāĻžāĻŽāĻžāĻ¨ā§āϝ āωāĻ¤ā§āĻĨāĻŋāϤ āĻļāĻ•ā§āϤ āĻ•ā§āώāϤ), āϭ⧇āϏāĻŋāĻ•āϞ (āĻ¸ā§āĻŦāĻšā§āĻ› āϤāϰāϞ āĻĻāĻŋāϝāĻŧ⧇ āĻ­āϰāĻž āĻ•ā§āώāϤ), āĻĒ⧁āĻ¸ā§āϟ⧁āϞāϏ (āĻšāϞ⧁āĻĻ āϤāϰāϞ⧇ āĻ­āϰāĻž āĻ•ā§āώāϤ), āĻāĻŦāĻ‚ āĻ•ā§āϰāĻžāĻ¸ā§āϟ/āĻ¸ā§āĻ•ā§āϝāĻžāĻŦ āϝāĻž āĻļ⧁āĻ•āĻŋāϝāĻŧ⧇ āϝāĻžāϝāĻŧ āĻāĻŦāĻ‚ āĻĒāĻĄāĻŧ⧇ āϝāĻžāϝāĻŧāĨ¤ .

āĻ•ā§āώāϤ⧇āϰ āϏāĻ‚āĻ–ā§āϝāĻž āĻ•āϝāĻŧ⧇āĻ• āĻĨ⧇āϕ⧇ āĻ•āϝāĻŧ⧇āĻ• āĻšāĻžāϜāĻžāϰ āĻĒāĻ°ā§āϝāĻ¨ā§āϤ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāĻŋāϤ āĻšāϝāĻŧāĨ¤ āϗ⧁āϰ⧁āϤāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇, āĻ•ā§āώāϤāϗ⧁āϞāĻŋ āĻāĻ•āĻ¤ā§āϰāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇ āϝāϤāĻ•ā§āώāĻŖ āύāĻž āĻ¤ā§āĻŦāϕ⧇āϰ āĻŦāĻĄāĻŧ āĻ…āĻ‚āĻļāϗ⧁āϞāĻŋ āĻā§āϞ⧇ āϝāĻžāϝāĻŧāĨ¤

āϰ⧋āĻ— āύāĻŋāĻ°ā§āĻŖāϝāĻŧ

āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āĻāĻ•āϟāĻŋ āϏ⧁āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āύāĻŋāĻ°ā§āĻŖāϝāĻŧ⧇āϰ āϜāĻ¨ā§āϝ āĻāĻ•āϜāύ āĻ¸ā§āĻŦāĻžāĻ¸ā§āĻĨā§āϝ āĻĒ⧇āĻļāĻžāĻĻāĻžāϰ āĻĻā§āĻŦāĻžāϰāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻāĻŦāĻ‚ āĻāĻ•āϟāĻŋ āĻŦāĻŋāĻļ⧇āώāĻœā§āĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāĻ—āĻžāϰ⧇ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

āĻ•ā§āϞāĻŋāύāĻŋāĻ•āĻžāϞ āĻĄāĻŋāĻĢāĻžāϰ⧇āύāĻļāĻŋāϝāĻŧāĻžāϞ āĻĄāĻžāϝāĻŧāĻžāĻ—āύ⧋āϏāĻŋāϏ āϝāĻž āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āωāϚāĻŋāϤ āϤāĻžāϰ āĻŽāĻ§ā§āϝ⧇ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĢ⧁āϏāϕ⧁āĻĄāĻŧāĻŋ āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻž āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ, āϝ⧇āĻŽāύ āϚāĻŋāϕ⧇āύāĻĒāĻ•ā§āϏ, āĻšāĻžāĻŽ, āĻŦā§āϝāĻžāĻ•āĻŸā§‡āϰāĻŋāϝāĻŧāĻžāϜāύāĻŋāϤ āĻ¤ā§āĻŦāϕ⧇āϰ āϏāĻ‚āĻ•ā§āϰāĻŽāĻŖ, āĻ¸ā§āĻ•ā§āϝāĻžāĻŦāĻŋāϏ, āϏāĻŋāĻĢāĻŋāϞāĻŋāϏ āĻāĻŦāĻ‚ āĻ“āώ⧁āϧ-āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĨ¤

āĻ…āϏ⧁āĻ¸ā§āĻĨāϤāĻžāϰ āĻĒā§āϰāĻĄā§āϰ⧋āĻŽāĻžāϞ āĻĒāĻ°ā§āϝāĻžāϝāĻŧ⧇ āϞāĻŋāĻŽā§āĻĢā§āϝāĻžāĻĄā§‡āύ⧋āĻĒā§āϝāĻžāĻĨāĻŋ āϚāĻŋāϕ⧇āύāĻĒāĻ•ā§āϏ āĻŦāĻž āϗ⧁āϟāĻŋāĻŦāϏāĻ¨ā§āϤ āĻĨ⧇āϕ⧇ āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏāϕ⧇ āφāϞāĻžāĻĻāĻž āĻ•āϰāĻžāϰ āϜāĻ¨ā§āϝ āĻāĻ•āϟāĻŋ āĻ•ā§āϞāĻŋāύāĻŋāĻ•āĻžāϞ āĻŦ⧈āĻļāĻŋāĻˇā§āĻŸā§āϝ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻĒāϞāĻŋāĻŽāĻžāϰ⧇āϜ āĻšā§‡āχāύ āϰāĻŋāĻ…ā§āϝāĻžāĻ•āĻļāύ (āĻĒāĻŋāϏāĻŋāφāϰ) āĻšāϞ āĻĒāĻ›āĻ¨ā§āĻĻ⧇āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāĻ—āĻžāϰ āĻĒāϰ⧀āĻ•ā§āώāĻž āϝāĻžāϰ āϝāĻĨāĻžāĻ°ā§āĻĨāϤāĻž āĻāĻŦāĻ‚ āϏāĻ‚āĻŦ⧇āĻĻāύāĻļā§€āϞāϤāĻžāĨ¤ āĻāϰ āϜāĻ¨ā§āϝ, āĻŽāĻžāĻ™ā§āĻ•āĻŋāĻĒāĻ•ā§āϏ⧇āϰ āϜāĻ¨ā§āϝ āϏāĻ°ā§āĻŦā§‹āĻ¤ā§āϤāĻŽ āĻĄāĻžāϝāĻŧāĻžāĻ—āύāĻ¸ā§āϟāĻŋāĻ• āύāĻŽā§āύāĻžāϗ⧁āϞāĻŋ āĻ¤ā§āĻŦāϕ⧇āϰ āĻ•ā§āώāϤ āĻĨ⧇āϕ⧇ - āĻ›āĻžāĻĻ āĻŦāĻž āϭ⧇āϏāĻŋāĻ•āϞ āĻāĻŦāĻ‚ āĻĒ⧁āĻ¸ā§āϟ⧁āϞāϏ āĻĨ⧇āϕ⧇ āϤāϰāϞ āĻāĻŦāĻ‚ āĻļ⧁āĻ•āύ⧋ āĻ•ā§āϰāĻžāĻ¸ā§āϟāĨ¤ āϝ⧇āĻ–āĻžāύ⧇ āϏāĻŽā§āĻ­āĻŦ, āĻŦāĻžāϝāĻŧā§‹āĻĒāϏāĻŋ āĻāĻ•āϟāĻŋ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒāĨ¤

Address

Dhaka

Website

Alerts

Be the first to know and let us send you an email when Care & Cure Organisation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category